iShares S&P 500 ETF

IVV

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

Clarity Pharmaceuticals Ltd

CU6

Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. The company is headquartered in Eveleigh, New South Wales. The company went IPO on 2021-08-25. The firm is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. The company is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. The company has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the provision of business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The Company’s lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).

Betashares Nasdaq 100 ETF

NDQ

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

Paladin Energy Ltd

PDN

Paladin Energy Ltd. engages in the development and operation of uranium mines. The company is headquartered in Perth, Western Australia. The firm also owns a portfolio of uranium exploration and development assets in the mining jurisdictions of Canada and Australia. Its segments include Australia, Namibia and Canada. The LHM is located in central western Namibia, approximately 80 kilometers (km) east of Swakopmund and 85 km northeast of the Walvis Bay deepwater harbor. Its Patterson Lake South (PLS) Project hosts the Triple R deposit, a high-grade and near-surface uranium deposit. The property comprises over 49 claims covering approximately 57,622 hectares. The company owns a number of greenfield exploration projects that are prospective for hosting high-grade uranium, including West Cluff, Larocque, Seahawk, Merlin, Corsair and Typhoon. Its projects also include Michelin (Labrador, Canada), Mount Isa and Manyingee projects in both Queensland and Western Australia.